NeurologyLive® Friday 5 — January 5, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: 5 Clinical Trial Readouts in Neurology to Look for in 2024

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2023 that neurology health care professionals should keep their eyes on.

2: Preclinical Neuroinflammation Modulation and Neuroprotection With Fosgonimeton in AD: Kevin Church, PhD

The chief scientific officer at Athira Pharma talked about preclinical results presented at the 2023 Society for Neuroscience Annual Meeting on fosgonimeton, a potential treatment for Alzheimer disease and other neurodegenerative diseases. [WATCH TIME: 6 minutes]

3: FDA Action Update, December 2023: Approval and Clearances

Catch up on any of the neurology news headlines you may have missed over the course of December 2023, compiled all into one place by the NeurologyLive® team.

4: NeuroVoices: Jennifer Gudeman, PharmD, on the Effect of Once-Nightly Sodium Oxybate in Narcolepsy Subtypes

The senior vice president of medical and clinical affairs for Avadel Pharmaceuticals provided perspective on a recently published analysis demonstrating the benefits of once-nightly sodium oxybate in narcolepsy type 1 and type 2.

5: A Dive Into the Neurological Impact of Long COVID and Hyperbaric Oxygen Therapy: Amir Hadanny, MD, PhD

The chief medical research officer and head of research at Aviv Clinics discussed the impact of long COVID on patients and shared findings from a recently published study on using hyperbaric oxygen therapy protocol as a treatment for these patients. [WATCH TIME: 8 minutes]